ESR1 and neoplasm: Patients undergoing PCa treatment must be aware that PAEs can interfere with therapeutic efficacy; for instance, DBP may promote tumor progression by competitively binding to the AR or activating ERα, potentially undermining androgen deprivation therapy (ADT) (Zhang T. et al., 2021).